Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shs12,450 shs
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.67
-5.6%		$1.77
$1.36
▼
$80.36
$2.96M-1.21392,580 shs105,236 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.91
-2.1%		$3.56
$1.43
▼
$58.75
$2.83M1.8385,843 shs13,746 shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$1.20
+1.3%		$1.47
$1.05
▼
$8.62
$3.14M2.54110,563 shs150,822 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
GRI Bio, Inc. stock logo
GRI
GRI Bio
-5.65%+13.61%+3.09%-17.73%-95.41%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-2.05%+1.06%-27.38%-57.17%-96.71%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
+1.27%+6.70%-22.90%-14.03%-77.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shs12,450 shs
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.67
-5.6%		$1.77
$1.36
▼
$80.36
$2.96M-1.21392,580 shs105,236 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.91
-2.1%		$3.56
$1.43
▼
$58.75
$2.83M1.8385,843 shs13,746 shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$1.20
+1.3%		$1.47
$1.05
▼
$8.62
$3.14M2.54110,563 shs150,822 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
GRI Bio, Inc. stock logo
GRI
GRI Bio
-5.65%+13.61%+3.09%-17.73%-95.41%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-2.05%+1.06%-27.38%-57.17%-96.71%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
+1.27%+6.70%-22.90%-14.03%-77.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athersys, Inc. stock logo
ATHX
Athersys
0.00
N/AN/AN/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
2.00
Hold$32.001,816.17% Upside
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
2.00
Hold$13.851,059.00% Upside

Current Analyst Ratings Breakdown

Latest ATHX, GRI, SXTP, and NXTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/1/2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $32.00
5/22/2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$4.20 ➝ $3.70
5/20/2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athersys, Inc. stock logo
ATHX
Athersys
$146K0.00N/AN/A($1.33) per share0.00
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$4.16 per shareN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$210K13.19N/AN/A$39.70 per share0.05
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$1.41M2.25N/AN/A($5.85) per share-0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$11.96M-$74.16N/AN/AN/AN/A-199.52%-143.23%N/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$114.15N/AN/AN/AN/A-238.19%-185.59%N/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$7.36M-$8.92N/AN/AN/A-574.91%N/A-131.48%N/A

Latest ATHX, GRI, SXTP, and NXTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$1.19-$0.91+$0.28-$0.91N/AN/A
8/14/2026Q2 2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$0.74-$0.90-$0.16-$0.90$0.19 million$0.21 million
5/15/2026Q1 2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$0.76-$1.28-$0.52-$1.28$0.44 million$0.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.91114.37%N/AN/A N/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
14.20
14.21
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.01
4.73
4.73
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/A
3.34
2.85

Institutional Ownership

CompanyInstitutional Ownership
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
7.96%

Insider Ownership

CompanyInsider Ownership
Athersys, Inc. stock logo
ATHX
Athersys
0.03%
GRI Bio, Inc. stock logo
GRI
GRI Bio
8.73%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
1.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
GRI Bio, Inc. stock logo
GRI
GRI Bio
11.77 million1.62 millionNot Optionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
21.45 million1.36 millionN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
32.66 million2.61 millionNot Optionable

Recent News About These Companies

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
August 14 at 3:47 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345584/0/en/60-degrees-pharmaceuticals-announces-second-quarter-2026-results.html
60 Degrees Pharmaceuticals (SXTP) Projected to Post Earnings on Wednesday
August 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30953712
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336358/0/en/60-degrees-pharmaceuticals-inc-announces-private-placement-priced-at-the-market-under-nasdaq-rules.html
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335549/0/en/60-degrees-pharmaceuticals-announces-minimum-enrollment-achieved-in-hospitalized-babesiosis-study-interim-data-readout-planned-by-october-6-2026.html
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324057/0/en/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases.html
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis ...
July 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-with-severe-fatigue-1036290098
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320572/0/en/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-.html
60 Degrees Pharmaceuticals (NASDAQ:SXTP) CEO Geoffrey Dow Acquires 7,350 Shares
June 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-sxtp-insider-buying-and-selling-2026-06-16/
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310432/0/en/60-degrees-pharmaceuticals-signs-exclusive-patent-license-agreement-with-florida-state-university-for-non-prescription-use-of-australian-chestnut-extract-as-a-botanical-supplement.html
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301055/0/en/60-degrees-pharmaceuticals-announces-early-enrollment-of-first-seasonal-patient-in-clinical-trial-of-tafenoquine-for-patients-hospitalized-with-babesiosis.html
HC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)
May 21, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/hc-wainwright-co-downgrades-60-degrees-pharmaceuticals-sxtp/ar-AA23H6gv
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295850/0/en/60-degrees-pharmaceuticals-announces-first-quarter-2026-results.html
60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/60-degrees-pharmaceuticals-sxtp-price-target-decreased-by-19-89-to-14-38/ar-AA21YV1N
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
April 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website-1036024547
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
April 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2894346/60-degrees-pharmaceuticals-inc-sxtp-upgraded-to-buy-here-s-what-you-should-know
Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 2, 2026  |  freep.comF
Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 2, 2026  |  freep.comF
60 Degrees Pharmaceuticals Announces 2025 Annual Results
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265329/0/en/60-degrees-pharmaceuticals-announces-2025-annual-results.html
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258123/0/en/60-degrees-pharmaceuticals-files-new-dietary-ingredient-notification-ndin-with-fda-for-australian-chestnut-extract.html
60 Degrees Pharmaceuticals Updates Opinion for ATM Program
March 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SXTP/pressreleases/744494/60-degrees-pharmaceuticals-updates-opinion-for-atm-program/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Meta logo glowing between glass server racks in a modern data center, symbolizing Meta’s AI and cloud infrastructure.
Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet
By Jeffrey Neal Johnson | July 20, 2026
Electrical transformer and substation equipment stand beside a large data center building with illuminated server racks at dusk.
AI Data Centers Need Power, and These 2 Industrials Are Cashing In
By Jeffrey Neal Johnson | July 20, 2026
Bear statue on a trading desk surrounded by red downward stock charts on multiple monitors in a trading floor.
Bearish Pressure Is Building Around These 3 Stocks
By Jessica Mitacek | August 3, 2026
IonQ logo surrounded by quantum computing hardware, highlighting IONQ stock and quantum technology sector demand.
IonQ Sparks a Quantum Grid Revolution
By Jeffrey Neal Johnson | August 7, 2026
An oil pump jack and drilling rig stand on an arid plain at sunset.
Oil Prices Are Surging and These 4 Stocks Are Cashing In
By Bridget Bennett | July 27, 2026
Athersys stock logo

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.67 -0.10 (-5.65%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.70 +0.03 (+1.80%)
As of 08/14/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$1.91 -0.04 (-2.05%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.92 +0.01 (+0.52%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.20 +0.02 (+1.27%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.17 -0.02 (-2.01%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas